Form 4: Talis Biomedical Corp: Director Leonard Braden Michael Increases Stake

Director Leonard Braden Michael reports acquisition of Talis Biomedical Corp shares through BML Investment Partners, L.P.

Summary

• On August 26, 2024, Leonard Braden Michael indirectly acquired 13,167 shares of Talis Biomedical Corp (TLIS) common stock at a price of $3.8978 per share.
• This acquisition was made through BML Investment Partners, L.P.
• Following this transaction, the total number of shares indirectly held by Mr. Leonard through BML Investment Partners, L.P. was 216,736.
• On August 28, 2024, Mr. Leonard indirectly acquired 1,215 shares of Talis Biomedical Corp (TLIS) common stock at a price of $3.9627 per share.
• Following this transaction, the total number of shares indirectly held by Mr. Leonard through BML Investment Partners, L.P. was 217,951.
• BML Capital Management, LLC, where Mr. Leonard is the managing member, serves as the general partner of BML Investment Partners, L.P.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally a good sign, but the form itself is simply a report of transactions.

Positives

• The director's increased investment could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that those with the most knowledge of the company believe its stock is undervalued.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal.

Key Dates

Keywords

Talis Biomedical Corp, Leonard Braden Michael, BML Investment Partners, share acquisition, Form 4, insider trading